The increasing cost of drugs and related products and services in developing countries results in a considerable increase in the amount of the national budget that is allocated, directly or indirectly, to demands for pharmaceuticals and vaccines in the public and private sectors.
The value of drugs produced globally in 1975 (excluding socialist countries for which figures are not available) was around US$40000 million. The developing world accounted for only one-tenth of this figure, over half of which involved only three countries: Brazil, India and Mexico. These imports included finished pharmaceutical products, bulk drugs in final dosage form for repackaging, medicinal chemicals for dosage formulation and, in some cases, chemical intermediates for further processing.
Most developing countries are now faced with rapidly increasing drug importation bills in connection with the expansion of health care, particularly primary health care, and the increase in population. For developing countries, importation of pharmaceuticals is one of the fastest-growing drains on hard foreign currency and prices of imported essential drugs are very often higher than in the country of origin.
Most developing countries lack a basic supporting chemical industry, and pharmaceutical production is mainly confined to formulation and packaging. Of the developing countries, 45 have no pharmaceutical manufacturing industry at all, 43 have only simple formulation and packaging industries, and only 7 have some basis for a real pharmaceutical industry, the majority of these activities being handled by transnational corporations through licensing and patent arrangements or direct capital investment.
Today there is firm evidence that the cost of imported drugs and technology for pharmaceutical production is very high. The most commonly used justification is the argument of the high cost of research and development which is mostly carried out by a few transnational corporations in industrialized countries. However, it should be noted that much of this research is directed towards the development of drugs that do not meet the basic health needs of developing countries. There is also great pressure to use brand names rather than generic names (INN) for 0141-0768/81/030175-03/$01.00/0 pharmaceutical products. Use of the latter could facilitate the availability of alternative, cheaper drugs that are still satisfactory from the medical point of view.
World pharmaceutical consumption in 1978 clearly shows the imbalance of drug supply and consumption between developed and developing countries. Generally, health product markets will grow rapidly up to 1985, a growth of 10% per annum being estimated for pharmaceuticals worldwide. Furthermore, the largest growth forecast is in Asia, Latin America and developing countries in general.
The world structure of the pharmaceutical industry is extremely complex and this industry is unique as regards the scope and depth of its operations in international markets. A few developing countries with a well-developed pharmaceutical industry are participating in international trade. However, technological innovations are mainly developed by transnational corporations which, by pooling capital, technology and modern management on an international scale, have been able to continue to develop and market new products worldwide in accordance with the present world economy.
The following are some of the most relevant indicators of the situation of the pharmaceutical sector in developing countries that could be considered when analysing this sector: (I) The share of transnational pharmaceutical companies in developing countries is between 75% and 85%, with more or less the same leading products in the majority of developing countries. (2) Generally no' more than 25 to 30 pharmaceutical producers supply about 80% of the drugs consumed in developing countries. (3)' The technological changes and the price structure of pharmaceuticals can be determined by medical and nonmedical factors, among the latter technological and commercial pressures. (4) The highly concentrated structure of the pharmaceutical industry is protected by patents and trade names, in addition to the specificand highly developed know-how. (5) Several analyses show that the drug consumption patterns in developing countries do not always , parallel the pattern of the most common prevalent diseases. This reflection of drug utilization is the result of the interplay of pressures on the pharmaceutical market, such as economic pressures, academic-scientific pressures, marketing and social pressures, etc. (6) Price transfer practices vary widely from country to country, iD 1981 The Royal Society of Medicine and it seems that the key factor is the relationship between host country and guest company. (7) The lack of a national comprehensive drug policy, as part of national health planning, creates in most developing countries a gap between drug demands and the actual health need for essential drugs.
Despite the high proportion of the health care budget that is spent on pharmaceuticals, it has been estimated that in many developing countries 60-70% of the population, mainly in rural areas, do not have constant access to the most essential drugs. This shortage of pharmaceuticals has two main causes: economic (because of the low income and limited productivity of the people in relation to current prices of available drugs), and geographical (because developing countries, and particularly the landlocked countries and small islands, are far from the production and technological centres of the world). Naturally, the shortage of pharmaceuticals can be measured by economic analysis but this alone cannot measure qualitative elements such as the type of pharmaceuticals available, their quality and safety, and their proper utilization by health personnel.
If economic indicators are not contrasted with relevant social indicators, there is a danger of misinterpreting the real impact of the economic dimension of the problem in developing countries; and the real impact of the actual transfer of technology that will take place in the pharmaceutical sector due to new concepts on national health policies, especially primary health care, linked with a comprehensive drug policy. The total drug expenditure and per capita increase in drug consumption that could be statistically shown may be concentrated in a privileged group of the society. However, if increase in drug expenditure is accompanied by a reduction in mortality and morbidity rates, this increase is likely to represent a major improvement in drug utilization and population coverage, since this reduction would not be confined to privileged groups.
The developing countries have come to realize that the conventional traditional approach is inappropriate for meeting the basic health needs, especially in drugs and vaccines, of their vast population, within a reasonable period of time and at a cost they can afford.
The question has been raised whether pharmaceutical products, particularly essential drugs (those indispensable for meeting the basic health needs of the population), should be considered as ordinary commercial commodities subject to the normal market forces of supply and demand.
It is clear that, to ensure the optimal use of limited financial resources, the available drugs in developing countries should be restricted to those proved to be therapeutically effective, to have acceptable safety, to satisfy health needs and to be reasonably priced. These drugs are 'essential drugs' and the implementation of their utilization in developing countries may completely change the present profile of the pharmaceutical sector in the world, modifying the technological and economic structure of the producing and consuming centres in developed and developing countries.
Several developing countries have undertaken the task of finding solutions to the problem of shortage of essential drugs for their health care programmes.
In 1975 the Twenty-eighth World Health Assembly considered a comprehensive report of the Director-General which reviewed the main components of drug policies, involving not only the health sector but also the industry, trade and financial sectors. This report also outlined problems both in developed and developing countries, and emphasized the need for adequate policies in order to meet the needs of developing countries where large segments of the population do not have access to the most essential drugs and vaccines indispensable to effective health care. In the pertinent resolution the World Health Assembly stressed the need to develop drug policies linking drugs research, production and distribution to real health needs, and requested the Director-General inter alia to advise countries on selection and procurement, at reasonable cost, of essential drugs of established quality.
Following this and other resolutions at global and regional levels, WHO has initiated and stimulated several activities, including technical cooperation among developing countries (TCDC) in interested developing countries, aimed towards the achievement of better pharmaceutical supply.
TCDC in the pharmaceutical sector is a multicountry effort that is under way in some regions: for example, preparing a combined list of essential drugs in the South Pacific islands, bulk purchasing in the Caribbean countries, the production of raw materials and intermediates in the countries of the Andean Pact in South America, and drug legislation and quality control in the ASEAN countries. The pharmaceutical sector, because of its especially complex characteristics, provides a unique opportunity for TCDC to flourish, as it plays a role within both national economic and health planning. .
The main objective of TCDC in the pharmaceutical sector is the identification of problem areas in each individual country within the framework of its own socioeconomic conditions, and possible areas for future technical cooperation, while strengthening national and regionalcapabilities, especially when dealing with sources of technology and finance.
United Nations agencies are increasingly under pressure from developing countries, not only to help them develop more efficient strategies, but also to assist in developing a multisectoral approach to the solutions. In December 1976, a task force of United Nations agencies (WHO, UNIDO, UNCTAD, UNDP, UNICEF and UNAPEC) began, working 'to provide a coordinated response by the United Nations system to the needs of the developing countries in the pharmaceutical sector'.
WHO, together with other United Nations agencies, is participating in a project entitled 'Economic and Technical Cooperation among Developing Countries in the Pharmaceutical Sector', the executing agency being the Government of Guyana. This project is unique in its nature and approach.
WHO has initiated, within its drug policies and management programme, an action programme on essential drugs, which is a comprehensive response to the unbalanced economic and technological situation between developed and developing countries in the pharmaceutical sector. This programme forms part of the strategy for implementing the aim of health for all by the year 2000.
In short, pharmaceuticals is one of the components of the health sector where a move has been made towards achieving the objectives of the New International Economic Order. This is true as regards the development of appropriate technology (drawing up lists of essential drugs and improving their utilization), the transfer of such technology (concerning the production and control of essential drugs), and better trade (through bulk purchasing agreements and strengthening the bargaining power of developing countries). In this field there has been both technical cooperation among developing countries (preparing consolidated lists of essential drugs, regional and subregional cooperation on drug quality control arrangements) and economic cooperation among developing countries (trade and financial agreements and price information and transfer agreements).
The activities in pharmaceuticals, although oriented to health, are multisectoral in nature, with implications that are of social, economic and technological relevance, and these activities may perhaps serve as examples for sectors other than health. It is for the developing countries themselves to decide on such matters as which drugs they need and in what quantities, the precise way in which they are to be utilized, how they are to be supplied, and where and how drug quality is 0141-0768/81/030177-04/$01.00/0 to be controlled. What is needed now is the transfer of resources to help developing countries to establish their own pharmaceutical supply systems appropriate to their needs. F S Antezana
Senior Scientist Drug Policies and Management WHO, Geneva

Cost effectiveness of prophylaxis of venous thromboembolism
Venous thromboembolism is a common complication of surgical operations. It frequently arises in patients in whom other risk factors are present. These include advanced age, obesity, malignant disease, cardiac failure, a previous history of venous disorders, immobilization, the use of oestrogen-containing oral contraceptive preparations, and trauma to the pelvic region or lower extremities. It is estimated (Coon et al. 1973 ) that in the United States, each year, some quarter of a million new cases of deep vein thrombosis (DVT) become clinically apparent and that up to 200000 deaths occur due primarily to pulmonary embolism (PE). An estimated 7 million people suffer from stasis changes following venous thrombosis and perhaps half a million of these have frank venous ulceration. Early studies by Morrell et al. (1963) from Oxford suggest that the incidence of venous thromboembolism is increasing, and that the increase is not just a manifestation of greater awareness resulting from improved diagnostic methods.
A recent report (Salzman & Davies 1980) from the Department of Surgery' at Harvard Medical School has attempted to analyse the cost and effectiveness of several methods of prevention in patients at risk of developing venous thromboembolism.
In the introduction, the authors point out that the literature on the prophylaxis of venous thromboembolism is legion and that the results of apparently similar studies may often be conflicting and, therefore, confusing to the practitioner. The relatively recent advent of investigations such as 12sI-fibrinogen scanning of the legs, ascending phlebography, Doppler ultrasound and impedance plethysmography, ventilation! perfusion lung scanning and pulmonary angiography, has improved diagnostic accuracy. Detection of venous thromboembolism by these
